HCW Biologics Inc. announced that it has received formal notice from The Nasdaq Stock Market LLC confirming that the company has regained compliance with all Nasdaq Capital Market listing requirements for continued listing. This includes the minimum stockholders’ equity requirement (Rule 5550(b)(1)), for which notice was received on June 24, 2025.
The company had previously received formal notice on May 13, 2025, confirming compliance with the bid price requirement (Rule 5550(a)(2)), the public float requirement (Rule 5550(a)(4)), and the market value of publicly held shares requirement (Rule 5550(a)(5)). These matters are now closed.
While the company now meets all listing requirements, it will remain subject to a 'Panel Monitor' until June 23, 2026. During this period, any future non-compliance with the Equity Rule would require a direct hearing before the Panel, without the opportunity to submit a compliance plan to staff.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.